Browse > Article
http://dx.doi.org/10.5352/JLS.2013.23.3.448

Inflammatory Bowel Disease and Cytokine  

Choi, Eun Young (Department of Biological Science, Silla University)
Cho, Kwang Keun (Department of Animal Resources Technology, Gyeongnam National University of Science and Technology)
Choi, In Soon (Department of Biological Science, Silla University)
Publication Information
Journal of Life Science / v.23, no.3, 2013 , pp. 448-461 More about this Journal
Abstract
Inflammatory bowel disease, known as Crohn's disease and ulcerative colitis, is an unexplained disease characterized by chronic inflammation that repeats a cycle of relapse, improvement, and complications. The cause of inflammatory bowel disease is not clearly known, but it is predicted that a complex of various factors precipitate its occurrence. In particular, inflammatory mediators, such as cytokine, induce an increase in cell-mediated inflammatory responses. Focal tissue damage then occurs in the intestinal mucosa because of the weakening of the immune-modulating functions of cotton. Immune and inflammatory responses do not decrease appropriately but continue until they lead to chronic inflammation. Current research has focused on the cytokine genes, which have important roles in these inflammatory responses. Cytokine is a glycoprotein that is produced mostly in activated immune cells. It connects the activation, multiplication, and differentiation between immune cells, which causes focal tissue damage and inflammatory response. Moreover, butyrate, which originates in dietary fiber and plays an important role in the structure and function of the intestinal area, shows control functions in the intestinal immune system by decreasing the proinflammatory cytokine and increasing the anti-inflammatory cytokine. Therefore, this research investigated the molecular mechanism of the anti-inflammatory effects of butyrate to comprehend the cytokine controlling abilities of butyrate in the immune cells. Butyrate is expected to have potential in new treatment strategies for inflammatory bowel disease.
Keywords
Inflammatory bowel disease; butyrate; proinflammatory cytokine; anti-inflammatory cytokine; Th17 Cell;
Citations & Related Records
Times Cited By KSCI : 3  (Citation Analysis)
연도 인용수 순위
1 Di Sabatino, A., Morera, R., Ciccocioppo, R., Cazzola, P., Gotti, S., Tinozzi, F. P., Tinozzi, S. and Corazza, G. R. 2005. Oral butyrate for mildly to moderately active Crohn's disease. Aliment Pharmacol Ther 22, 789-794.   DOI   ScienceOn
2 Duerr, R. H., Taylor, K. D., Brant, S. R., Rioux, J. D., Silverberg, M. S., Daly, M. J., Steinhart, A. H., Abraham, C., Regueiro, M., Griffiths, A., Dassopoulos, T., Bitton, A., Yang, H., Targan, S., Datta, L. W., Kistner, E. O., Schumm, L. P., Lee, A. T., Gregersen, P. K., Barmada, M. M., Rotter, J. I., Nicolae, D. L. and Cho, J. H. 2006. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 314, 1461-1463.   DOI   ScienceOn
3 Fedorak, R. N., Gangl, A., Elson, C. O., Rutgeerts, P., Schreiber, S., Wild, G., Hanauer, S. B., Kilian, A., Cohard, M., LeBeaut, A. and Feagan, B. 2000. Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. Gastroenterology 119, 1473-1482.   DOI   ScienceOn
4 Fukae, J., Amasaki, Y., Yamashita, Y., Bohgaki, T., Yasuda, S., Jodo, S., Atsumi, T. and Koike, T. 2005. Butyrate suppresses tumor necrosis factor alpha production by regulating specific messenger RNA degradation mediated through a cis-acting AU-rich element. Arthritis Rheum 52, 2697-2707.   DOI   ScienceOn
5 Goustin, A. S., Leof, E. B., Shipley, G. D. and Moses, H. L. 1986. Growth factors and cancer. Cancer Res 46, 1015-1029.
6 Goyette, P., Labbe, C., Trinh, T. T., Xavier, R. J. and Rioux, J. D. 2007. Molecular pathogenesis of inflammatory bowel disease: genotypes, phenotypes and personalized medicine. Ann Med 39, 177-199.   DOI   ScienceOn
7 Abraham, C. and Cho, J. 2009. Interleukin-23/Th17 pathways and inflammatory bowel disease. Inflamm Bowel Dis 15, 1090-1100.   DOI   ScienceOn
8 Alex, P., Zachos, N. C., Nguyen, T., Gonzales, L., Chen, T. E., Conklin, L. S., Centola, M. and Li, X. 2009. Distinct cytokine patterns identified from multiplex profiles of murine DSS and TNBS-induced colitis. Inflamm Bowel Dis 15, 341-352.   DOI   ScienceOn
9 Brand, S. 2009. Crohn's disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn's disease. Gut 58, 1152-1167.   DOI   ScienceOn
10 Hamer, H. M., Jonkers, D., Venema, K., Vanhoutvin, S., Troost, F. J. and Brummer, R. J. 2008. Review article: the role of butyrate on colonic function. Aliment Pharmacol Ther 27, 104-119.
11 Hanai, H., Takeda, Y., Eberhardson, M., Gruber, R., Saniabadi, A. R., Winqvist, O. and Lofberg, R. 2011. The mode of actions of the Adacolumn therapeutic leucocytapheresis in patients with inflammatory bowel disease: a concise review. Clin Exp Immunol 163, 50-58.   DOI   ScienceOn
12 Harrington, L. E., Hatton, R. D., Mangan, P. R., Turner, H., Murphy, T. L., Murphy, K. M. and Weaver, C. T. 2005. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 6, 1123-1132.   DOI   ScienceOn
13 Herfarth, H. H., Mohanty, S. P., Rath, H. C., Tonkonogy, S. and Sartor, R. B. 1996. Interleukin 10 suppresses experimental chronic, granulomatous inflammation induced by bacterial cell wall polymers. Gut 39, 836-845.   DOI   ScienceOn
14 Hommes, D. W., Mikhajlova, T. L., Stoinov, S., Stimac, D., Vucelic, B., Lonovics, J., Zakuciova, M., D'Haens, G., Van Assche, G., Ba, S., Lee, S. and Pearce, T. 2006. Fontolizumab, a humanised anti-interferon gamma antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease. Gut 55, 1131-1137.
15 Huuskonen, J., Suuronen, T., Nuutinen, T., Kyrylenko, S. and Salminen, A. 2004. Regulation of microglial inflammatory response by sodium butyrate and short-chain fatty acids. Br J Pharmacol 141, 874-880.   DOI   ScienceOn
16 Izcue, A., Coombes, J. L. and Powrie, F. 2009. Regulatory lymphocytes and intestinal inflammation. Annu Rev Immunol 27, 313-338.   DOI   ScienceOn
17 Jang, B. I. 2007. Clinical Update: Inflammatory bowel disease. Yeungnam Uni J Med 24, S221-233.
18 Kanneganti, T. D., Lamkanfi, M. and Nunez, G. 2007. Intracellular NOD-like receptors in host defense and disease. Immunity 27, 549-559.   DOI   ScienceOn
19 Dionne, S., Hiscott, J., D'Agata, I., Duhaime, A. and Seidman, E. G. 1997. Quantitative PCR analysis of TNF-alpha and IL-1 beta mRNA levels in pediatric IBD mucosal biopsies. Dig Dis Sci 42, 1557-1566.   DOI   ScienceOn
20 Jung, W. T., Shin, W. C., Choi, W. C., Lee, J. H. and Kim, K. Y. 1999. Chemokine Gene Expression in the Colonic Mucosa of Patients with Ulcerative Colitis and Crohn's Disease - Analysis by Quantitative reverse Transcriptional polymerase Chain Reaction using synthetic Standard RNA. Inje Med J 20, 257-269.
21 Kaser, A., Zeissig, S. and Blumberg, R. S. 2010. Inflammatory bowel disease. Annu Rev Immunol 28, 573-621.   DOI   ScienceOn
22 Kim, B. J., Song, S. M., Kim, K. M., Lee, Y. J., Rhee, K. W., Jang, J. Y., Park, S. J. and Yoon, C. H. 2010. Characteristics and trends in the incidence of inflammatory bowel disease in Korean children: a single-center experience. Dig Dis Sci 55, 1989-1995.   DOI
23 Kim, J. M. 2010. Inflammatory bowel diseases and enteric microbiota. Korean J Gastroenterol 55, 4-18.   DOI   ScienceOn
24 Kim, J. M. 2011. Inflammatory bowel diseases and inflammasome. Korean J Gastroenterol 58, 300-310.   DOI   ScienceOn
25 Kim, K. H. 2009. Effects of chitosan on the production of Th1 and Th2 cytokines in mice. J Life Sci 19, 411-416.   과학기술학회마을   DOI   ScienceOn
26 Kim, T. H., Kim, B. G., Shin, H. D., Kim, J. W., Kim, C. G., Kim, J. S., Jung, H. C. and Song, I. S. 2003. Tumor necrosis factor-${\alpha}$ and Interleukin-10 gene polymorphisms in Korean patients with inflammatory bowel disease. Korean J Gastroenterol 42, 377-386.   과학기술학회마을
27 Kobayashi, T., Okamoto, S., Hisamatsu, T., Kamada, N., Chinen, H., Saito, R., Kitazume, M. T., Nakazawa, A., Sugita, A., Koganei, K., Isobe, K. and Hibi, T. 2008. IL23 differentially regulates the Th1/Th17 balance in ulcerative colitis and Crohn's disease. Gut 57, 1682-1689.   DOI   ScienceOn
28 Kinoshita, M., Suzuki, Y. and Saito, Y. 2002. Butyrate reduces colonic paracellular permeability by enhancing PPARgamma activation. Biochem Biophys Res Commun 293, 827-831.   DOI   ScienceOn
29 Kirschner, B. S. 1998. Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease. Gastroenterology 115, 813-821.   DOI   ScienceOn
30 Klagsbrun, M. and D'Amore, P. A. 1991. Regulators of angiogenesis. Annu Rev Physiol 53, 217-239.   DOI   ScienceOn
31 Koenders, M. I. and van den Berg, W. B. 2010. Translational mini-review series on Th17 cells: are T helper 17 cells really pathogenic in autoimmunity? Clin Exp Immunol 159, 131-136.   DOI   ScienceOn
32 Koloski, N. A., Bret, L. and Radford-Smith, G. 2008. Hygiene hypothesis in inflammatory bowel disease: a critical review of the literature. World J Gastroenterol 14, 165-173.   DOI
33 Kuhn, R., Lohler, J., Rennick, D., Rajewsky, K. and Muller, W. 1993. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 75, 263-274.   DOI   ScienceOn
34 Lee, K. L., Kim, C. G., Kim, B. G., Chang, D. K., Lee, D. H., Kim, J. S., Jung, H. C. Lee, Y., Park, J. S. and Song, I. S. 2003. Down-regulatory effect of Interleukin-10 gene transfection for CXC chemokines in colonic epithelial cell. Korean J Gastroenterol 41, 447-455.   과학기술학회마을
35 Lewis, C. M., Whitwell, S. C., Forbes, A., Sanderson, J., Mathew, C. G. and Marteau, T. M. 2007. Estimating risks of common complex diseases across genetic and environmental factors: the example of Crohn disease. J Med Genet 44, 689-694.   DOI
36 Powrie, F., Leach, M. W., Mauze, S., Menon, S., Caddle, L. B. and Coffman, R. L. 1994. Inhibition of Th1 responses prevents inflammatory bowel disease in scid mice reconstituted with CD45RBhi CD4+ T cells. Immunity 1, 553-562.   DOI   ScienceOn
37 Liu, L., Li, L., Min, J., Wang, J., Wu, H., Zeng, Y., Chen, S. and Chu, Z. 2012. Butyrate interferes with the differentiation and function of human monocyte-derived dendritic cells. Cell Immunol 277, 66-73.   DOI   ScienceOn
38 MacDermott, R. P. and Stenson, W. F. 1988. Alterations of the immune system in ulcerative colitis and Crohn's disease. Adv Immunol 42, 285-328.   DOI
39 Jeon, C. H., Kim, J. H., Park, J. H., Ahn, K. S., Kim, H. J., Kim, E. H., Ahn, J. K., Cha, H. S. and Koh, E. M. 2003. Cytokine profiles in synovial fluid of rheumatoid arthritis. Korean J Med 64, 576-587.   과학기술학회마을
40 Mangan, P. R., Harrington, L. E., O'Quinn, D. B., Helms, W. S., Bullard, D. C., Elson, C. O., Hatton, R. D., Wahl, S. M., Schoeb, T. R. and Weaver, C. T. 2006. Transforming growth factor-beta induces development of the T(H)17 lineage. Nature 441, 231-234.   DOI   ScienceOn
41 Mosmann, T. R. and Sad, S. 1996. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 17, 138-146.   DOI   ScienceOn
42 Neurath, M. F. 2007. IL-23: a master regulator in Crohn disease. Nat Med 13, 26-28.   DOI   ScienceOn
43 O'Connor, W., Jr., Kamanaka, M., Booth, C. J., Town, T., Nakae, S., Iwakura, Y., Kolls, J. K. and Flavell, R. A. 2009. A protective function for interleukin 17A in T cell-mediated intestinal inflammation. Nat Immunol 10, 603-609.   DOI   ScienceOn
44 Pacheco, R. G., Esposito, C. C., Muller, L. C., Castelo-Branco, M. T., Quintella, L. P., Chagas, V. L., de Souza, H. S. and Schanaider, A. 2012. Use of butyrate or glutamine in enema solution reduces inflammation and fibrosis in experimental diversion colitis. World J Gastroenterol 18, 4278-4287.   DOI   ScienceOn
45 Reinisch, W., de Villiers, W., Bene, L., Simon, L., Racz, I., Katz, S., Altorjay, I., Feagan, B., Riff, D., Bernstein, C. N., Hommes, D., Rutgeerts, P., Cortot, A., Gaspari, M., Cheng, M., Pearce, T. and Sands, B. E. 2010. Fontolizumab in moderate to severe Crohn's disease: a phase 2, randomized, double- blind, placebo-controlled, multiple-dose study. Inflamm Bowel Dis 16, 233-242.   DOI   ScienceOn
46 Park, J. S., Lee, E. J., Lee, J. C., Kim, W. K. and Kim, H. S. 2007. Anti-inflammatory effects of short chain fatty acids in IFN-gamma-stimulated RAW 264.7 murine macrophage cells: involvement of NF-kappaB and ERK signaling pathways. Int Immunopharmacol 7, 70-77.   DOI   ScienceOn
47 Pender, S. L., Breese, E. J., Gunther, U., Howie, D., Wathen, N. C., Schuppan, D. and MacDonald, T. T. 1998. Suppression of T cell-mediated injury in human gut by interleukin 10: role of matrix metalloproteinases. Gastroenterology 115, 573-583.   DOI   ScienceOn
48 Kleessen, B., Kroesen, A. J., Buhr, H. J. and Blaut, M. 2002. Mucosal and invading bacteria in patients with inflammatory bowel disease compared with controls. Scand J Gastroenterol 37, 1034-1041.   DOI   ScienceOn
49 Roediger, W. E. 1980. Role of anaerobic bacteria in the metabolic welfare of the colonic mucosa in man. Gut 21, 793-798.   DOI   ScienceOn
50 Roediger, W. E. 1982. Utilization of nutrients by isolated epithelial cells of the rat colon. Gastroenterology 83, 424-429.
51 Rogy, M. A., Beinhauer, B. G., Reinisch, W., Huang, L. and Pokieser, P. 2000. Transfer of interleukin-4 and interleukin- 10 in patients with severe inflammatory bowel disease of the rectum. Hum Gene Ther 11, 1731-1741.   DOI   ScienceOn
52 Saemann, M. D., Bohmig, G. A., Osterreicher, C. H., Burtscher, H., Parolini, O., Diakos, C., Stockl, J., Horl, W. H. and Zlabinger, G. J. 2000. Anti-inflammatory effects of sodium butyrate on human monocytes: potent inhibition of IL-12 and up-regulation of IL-10 production. FASEB J 14, 2380-2382.
53 Sartor, R. B. 1991. Pathogenetic and clinical relevance of cytokines in inflammatory bowel disease. Immunol Res 10, 465-471.   DOI
54 Sandborn, W. J. and Targan, S. R. 2002. Biologic therapy of inflammatory bowel disease. Gastroenterology 122, 1592-1608.   DOI   ScienceOn
55 Sandborn, W. J., Feagan, B. G., Fedorak, R. N., Scherl, E., Fleisher, M. R., Katz, S., Johanns, J., Blank, M., Rutgeerts, P. and Ustekinumab Crohn's Disease Study, G. 2008. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology 135, 1130-1141.   DOI   ScienceOn
56 Sands, B. E. 1997. Biologic therapy for inflammatory bowel disease. Inflamm Bowel Dis 3, 95-113.
57 Perez, R., Stevenson, F., Johnson, J., Morgan, M., Erickson, K., Hubbard, N. E., Morand, L., Rudich, S., Katznelson, S. and German, J. B. 1998. Sodium butyrate upregulates Kupffer cell PGE2 production and modulates immune function. J Surg Res 78, 1-6.   DOI   ScienceOn
58 Targan, S. R., Hanauer, S. B., van Deventer, S. J., Mayer, L., Present, D. H., Braakman, T., DeWoody, K. L., Schaible, T. F. and Rutgeerts, P. J. 1997. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 337, 1029-1035.   DOI   ScienceOn
59 Tilg, H., Moschen, A. R., Kaser, A., Pines, A. and Dotan, I. 2008. Gut, inflammation and osteoporosis: basic and clinical concepts. Gut 57, 684-694.   DOI   ScienceOn
60 Tysk, C., Lindberg, E., Jarnerot, G. and Floderus-Myrhed, B. 1988. Ulcerative colitis and Crohn's disease in an unselected population of monozygotic and dizygotic twins. A study of heritability and the influence of smoking. Gut 29, 990-996.   DOI   ScienceOn
61 Reif, S., Klein, I., Lubin, F., Farbstein, M., Hallak, A. and Gilat, T. 1997. Pre-illness dietary factors in inflammatory bowel disease. Gut 40, 754-760.   DOI   ScienceOn
62 Camoglio, L., Te Velde, A. A., Tigges, A. J., Das, P. K. and Van Deventer, S. J. 1998. Altered expression of interferon- gamma and interleukin-4 in inflammatory bowel disease. Inflamm Bowel Dis 4, 285-290.
63 Usami, M., Kishimoto, K., Ohata, A., Miyoshi, M., Aoyama, M., Fueda, Y. and Kotani, J. 2008. Butyrate and trichostatin A attenuate nuclear factor kappaB activation and tumor necrosis factor alpha secretion and increase prostaglandin E2 secretion in human peripheral blood mononuclear cells. Nutr Res 28, 321-328.   DOI   ScienceOn
64 van Deventer, S. J., Elson, C. O. and Fedorak, R. N. 1997. Multiple doses of intravenous interleukin 10 in steroidrefractory Crohn's disease. Crohn's Disease Study Group. Gastroenterology 113, 383-389.   DOI   ScienceOn
65 Sartor, R. B. 1994. Cytokines in intestinal inflammation: pathophysiological and clinical considerations. Gastroenterology 106, 533-539.
66 Sashio, H., Tamura, K., Ito, R., Yamamoto, Y., Bamba, H., Kosaka, T., Fukui, S., Sawada, K., Fukuda, Y., Tamura, K., Satomi, M., Shimoyama, T. and Furuyama, J. 2002. Polymorphisms of the TNF gene and the TNF receptor superfamily member 1B gene are associated with susceptibility to ulcerative colitis and Crohn's disease, respectively. Immunogenetics 53, 1020-1027.   DOI   ScienceOn
67 van Driel, W. J., Kievit-Tyson, P., van den Broek, L. C., Zwinderman, A. H., Trimbos, B. J. and Fleuren, G. J. 1999. Presence of an eosinophilic infiltrate in cervical squamous carcinoma results from a type 2 immune response. Gynecol Oncol 74, 188-195.   DOI   ScienceOn
68 van Dullemen, H. M., van Deventer, S. J., Hommes, D. W., Bijl, H. A., Jansen, J., Tytgat, G. N. and Woody, J. 1995. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 109, 129-135.   DOI   ScienceOn
69 Vinolo, M. A., Rodrigues, H. G., Nachbar, R. T. and Curi, R. 2011. Regulation of inflammation by short chain fatty acids. Nutrients 3, 858-876.   DOI
70 Castrilli, G., Tatone, D., Diodoro, M. G., Rosini, S., Piantelli, M. and Musiani, P. 1997. Interleukin 1alpha and interleukin 6 promote the in vitro growth of both normal and neoplastic human cervical epithelial cells. Br J Cancer 75, 855-859.   DOI   ScienceOn
71 Ceciliani, F., Giordano, A. and Spagnolo, V. 2002. The systemic reaction during inflammation: the acute-phase proteins. Protein Pept Lett 9, 211-223.   DOI   ScienceOn
72 Chakravortty, D., Koide, N., Kato, Y., Sugiyama, T., Mu, M. M., Yoshida, T. and Yokochi, T. 2000. The inhibitory action of butyrate on lipopolysaccharide-induced nitric oxide production in RAW 264.7 murine macrophage cells. J Endotoxin Res 6, 243-247.   DOI
73 Chen, P. S., Wang, C. C., Bortner, C. D., Peng, G. S., Wu, X., Pang, H., Lu, R. B., Gean, P. W., Chuang, D. M. and Hong, J. S. 2007. Valproic acid and other histone deacetylase inhibitors induce microglial apoptosis and attenuate lipopolysaccharide- induced dopaminergic neurotoxicity. Neuroscience 149, 203-212.   DOI   ScienceOn
74 Cho, M. S., Song, S. M., Oh, S. H., Lee, Y. J. Jang, J. Y. and Kim, K. M. 2011. Tumor necrosis factor-${\alpha}$ gene polymorphisms in Korean children with inflammatory bowel disease. Korean J Pediatr Gastroenterol Nutr 14, 269-278.   DOI
75 Cummings, J. H. 1983. Fermentation in the human large intestine: evidence and implications for health. Lancet 1, 1206-1209.
76 D'Haens, G., Van Deventer, S., Van Hogezand, R., Chalmers, D., Kothe, C., Baert, F., Braakman, T., Schaible, T., Geboes, K. and Rutgeerts, P. 1999. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial. Gastroenterology 116, 1029-1034.   DOI   ScienceOn
77 Dijkstra, G., Moshage, H. and Jansen, P. L. 2002. Blockade of NF-kappaB activation and donation of nitric oxide: new treatment options in inflammatory bowel disease? Scand J Gastroenterol Suppl 236, 37-41.
78 Schreiber, S., Fedorak, R. N., Nielsen, O. H., Wild, G., Williams, C. N., Nikolaus, S., Jacyna, M., Lashner, B. A., Gangl, A., Rutgeerts, P., Isaacs, K., van Deventer, S. J., Koningsberger, J. C., Cohard, M., LeBeaut, A. and Hanauer, S. B. 2000. Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group. Gastroenterology 119, 1461-1472.   DOI   ScienceOn
79 Werts, C., Rubino, S., Ling, A., Girardin, S. E. and Philpott, D. J. 2011. Nod-like receptors in intestinal homeostasis, inflammation, and cancer. J Leukoc Biol 90, 471-482.   DOI   ScienceOn
80 Scheppach, W. and Weiler, F. 2004. The butyrate story: old wine in new bottles? Curr Opin Clin Nutr Metab Care 7, 563-567.   DOI   ScienceOn
81 Segain, J. P., Raingeard de la Bletiere, D., Bourreille, A., Leray, V., Gervois, N., Rosales, C., Ferrier, L., Bonnet, C., Blottiere, H. M. and Galmiche, J. P. 2000. Butyrate inhibits inflammatory responses through NFkappaB inhibition: implications for Crohn's disease. Gut 47, 397-403.   DOI   ScienceOn
82 Siegmund, B. 2002. Interleukin-1beta converting enzyme (caspase-1) in intestinal inflammation. Biochem Pharmacol 64, 1-8.   DOI   ScienceOn
83 Soderholm, J. D., Streutker, C., Yang, P. C., Paterson, C., Singh, P. K., McKay, D. M., Sherman, P. M., Croitoru, K. and Perdue, M. H. 2004. Increased epithelial uptake of protein antigens in the ileum of Crohn's disease mediated by tumour necrosis factor alpha. Gut 53, 1817-1824.   DOI   ScienceOn